Experience with the use of intravitreal bevacizumab in cases with type I retinopathy of prematurity in a Latin American country

C. Zuluaga-Botero; N. González; G. Escobar; E. Cantor; A. Martínez-Blanco

doi:10.1016/j.oftal.2024.03.012

Experience with the use of intravitreal bevacizumab in cases with type I retinopathy of prematurity in a Latin American country

C. Zuluaga-Botero, N. González, G. Escobar, E. Cantor, A. Martínez-Blanco

Department of Clinical Epidemiology and Biostatistics

Research output: Contribution to journal › Article › peer-review

Abstract

In retinopathy of prematurity (ROP) type I, the use of intravitreal bevacizumab (IVB), which is an inhibitor of endothelial growth factor (VEGF), has become popular despite not being a therapy approved by regulatory agencies. However, IVB has shown positive effects in halting disease progression at lower costs compared to other anti-VEGF therapies (ranibizumab or aflibercept). In this report, we present the experience during the treatment with IVB of 102 Colombian children with ROP type I, with a success rate of 98% (100). Complications occurred in 3.9% (4). Finally, we conclude that a single dose of IVB is an effective therapy for the management of ROP type I, with a lower risk of complications and retreatment.

Translated title of the contribution	Experiencia con el uso de bevacizumab intravítreo en el manejo de la retinopatía del prematuro tipo I en un país latinoamericano
Original language	English
Journal	Archivos de la Sociedad Espanola de Oftalmologia
DOIs	https://doi.org/10.1016/j.oftal.2024.03.012
State	Accepted/In press - 2024

Keywords

Aflibercept
Bevacizumab
Endothelial growth factor inhibitor
Retinopathy of prematurity

Access to Document

10.1016/j.oftal.2024.03.012

Cite this

@article{f6469e2319494e39a45107313b15afdc,

title = "Experience with the use of intravitreal bevacizumab in cases with type I retinopathy of prematurity in a Latin American country",

abstract = "In retinopathy of prematurity (ROP) type I, the use of intravitreal bevacizumab (IVB), which is an inhibitor of endothelial growth factor (VEGF), has become popular despite not being a therapy approved by regulatory agencies. However, IVB has shown positive effects in halting disease progression at lower costs compared to other anti-VEGF therapies (ranibizumab or aflibercept). In this report, we present the experience during the treatment with IVB of 102 Colombian children with ROP type I, with a success rate of 98% (100). Complications occurred in 3.9% (4). Finally, we conclude that a single dose of IVB is an effective therapy for the management of ROP type I, with a lower risk of complications and retreatment.",

keywords = "Aflibercept, Bevacizumab, Endothelial growth factor inhibitor, Retinopathy of prematurity",

author = "C. Zuluaga-Botero and N. Gonz{\'a}lez and G. Escobar and E. Cantor and A. Mart{\'i}nez-Blanco",

note = "Publisher Copyright: {\textcopyright} 2024 Sociedad Espa{\~n}ola de Oftalmolog{\'i}a",

year = "2024",

doi = "10.1016/j.oftal.2024.03.012",

language = "English",

journal = "Archivos de la Sociedad Espanola de Oftalmologia",

issn = "0365-6691",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Experience with the use of intravitreal bevacizumab in cases with type I retinopathy of prematurity in a Latin American country

AU - Zuluaga-Botero, C.

AU - González, N.

AU - Escobar, G.

AU - Cantor, E.

AU - Martínez-Blanco, A.

PY - 2024

Y1 - 2024

N2 - In retinopathy of prematurity (ROP) type I, the use of intravitreal bevacizumab (IVB), which is an inhibitor of endothelial growth factor (VEGF), has become popular despite not being a therapy approved by regulatory agencies. However, IVB has shown positive effects in halting disease progression at lower costs compared to other anti-VEGF therapies (ranibizumab or aflibercept). In this report, we present the experience during the treatment with IVB of 102 Colombian children with ROP type I, with a success rate of 98% (100). Complications occurred in 3.9% (4). Finally, we conclude that a single dose of IVB is an effective therapy for the management of ROP type I, with a lower risk of complications and retreatment.

AB - In retinopathy of prematurity (ROP) type I, the use of intravitreal bevacizumab (IVB), which is an inhibitor of endothelial growth factor (VEGF), has become popular despite not being a therapy approved by regulatory agencies. However, IVB has shown positive effects in halting disease progression at lower costs compared to other anti-VEGF therapies (ranibizumab or aflibercept). In this report, we present the experience during the treatment with IVB of 102 Colombian children with ROP type I, with a success rate of 98% (100). Complications occurred in 3.9% (4). Finally, we conclude that a single dose of IVB is an effective therapy for the management of ROP type I, with a lower risk of complications and retreatment.

KW - Aflibercept

KW - Bevacizumab

KW - Endothelial growth factor inhibitor

KW - Retinopathy of prematurity

UR - http://www.scopus.com/inward/record.url?scp=85190744532&partnerID=8YFLogxK

U2 - 10.1016/j.oftal.2024.03.012

DO - 10.1016/j.oftal.2024.03.012

M3 - Article

AN - SCOPUS:85190744532

SN - 0365-6691

JO - Archivos de la Sociedad Espanola de Oftalmologia

JF - Archivos de la Sociedad Espanola de Oftalmologia

ER -

Experience with the use of intravitreal bevacizumab in cases with type I retinopathy of prematurity in a Latin American country

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this